Industry News
Biotechnology Industry News
After taking a stab at becoming a…
After taking a stab at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical asset and returning to its drug discovery roots.
Daiichi Sankyo and Merck &…
Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial.
Founded by a team of…
Founded by a team of neuropsychiatric-focused Teva alums and the force behind Cobenfy maker Karuna, Syremis Therapeutics is off to the races with a $165 million series A to support the development of a dual
Athira Pharma has joined an…
Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.
The Coalition for Epidemic…
The Coalition for Epidemic Preparedness Innovations—already engaged in a strategic partnership with Moderna—has agreed to plug up to $54.3 million into a pivotal phase 3 trial for mRNA-1018, Moderna’s mRNA-based H5 pandemic influenza vaccine candidate.
Eli Lilly has shown patients…
Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s Wegovy.
GSK is embarking on a journey with…
GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.
Takeda’s closely watched and…
Takeda’s closely watched and highly valued dermatology pill zasocitinib has won out in two key phase 3 trials as the Japanese pharma looks to file the drug in the U.S. next year.
Neurology biotech Voyager…
Neurology biotech Voyager Therapeutics has laid off 30 employees, a spokesperson for the Massachusetts-based company confirmed to Fierce Biotech.
After a late-stage miss for…
After a late-stage miss for Vistagen's prospective social anxiety disorder treatment fasedienol, the company's chances at an FDA approval in the indication are looking slimmer.
The former director of the…
The former director of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases is suing Trump administration officials over her September firing, which she alleges violated her rights and was illegal under
Norgine secured an exclusive…
Norgine secured an exclusive license to commercialize Vir Biotechnology's combo hepatitis D prospect of tobevibart and elebsiran in Europe, Australia and New Zealand.
After layoffs this fall, Mythic…
After layoffs this fall, Mythic Therapeutics is winding down, while asthma-focused Areteia Therapeutics is reportedly shuttering mere months after reporting a phase 3 win for its oral biologic.
Bristol Myers Squibb has become…
Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour BioMed for a multiyear research deal.
University of California spinout…
University of California spinout Addition Therapeutics has uncloaked, revealing “breakthrough” PRINT technology it hopes will fuel a new wave of genetic medicine.
Nektar Therapeutics is planning to…
Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia areata, even after the asset narrowly missed the main goal of a midstage trial.
Vivek Ramaswamy has found time out…
Vivek Ramaswamy has found time out of his campaign for governor of Ohio to launch a new biotech. The new firm, Ambros Therapeutics, launched Tuesday with a $125 million series A and plans to develop
The FDA has delayed an approval…
The FDA has delayed an approval decision for Aldeyra Therapeutics’ lead dry eye disease candidate, adding another detour to the candidate’s winding road to potentially reach the market.
U.S.-based Yarrow Bioscience is…
U.S.-based Yarrow Bioscience is branching out, picking an autoimmune thyroid disease drug from China as its lead candidate.
A flurry of deal-making hasn’t…
A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and crafting a multi-year cancer collaboration with Caris Life Sciences.